SEC filing · 8-K

NEUROONE MEDICAL TECHNOLOGIES Corp: Quarterly results

NeuroOne reported preliminary fourth quarter product revenue of approximately $3.8 million and secured a record $4.5 million purchase order.

Filed October 5, 2026

Positive for the company

What happened

Fourth quarter fiscal 2026 product revenue reached approximately $3.8 million, representing year-over-year growth of 38.4% compared to approximately $2.7 million in the fourth quarter of fiscal 2025.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to NEUROONE MEDICAL TECHNOLOGIES Corp

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.